| 摘要 |
A combination of temsirolimus and sunitinib malate in the treatment of cancer is provided. Also provided are regimens and kits for treatment of renal cell carcinoma, containing temsirolium and sunitinib malate, optionally in combination with other anti-neoplastic or immune modulators.
|
